Carrick

CARRICK CAPITAL PARTNERS NAMES SUZANNE PASSALACQUA CFO

Retrieved on: 
Tuesday, October 10, 2023
Software, Investment, DLJ, Carrick, McKesson Corporation, CFO, Family, SAN, Passalacqua, Management

SAN FRANCISCO and NEWPORT BEACH, Calif., Oct. 10, 2023 /PRNewswire/ -- Carrick Capital Partners, a growth-oriented investment firm focused on software and software-enabled businesses, today announced the appointment of Suzanne Passalacqua to the position of Managing Director and Chief Financial Officer.

Key Points: 
  • SAN FRANCISCO and NEWPORT BEACH, Calif., Oct. 10, 2023 /PRNewswire/ -- Carrick Capital Partners, a growth-oriented investment firm focused on software and software-enabled businesses, today announced the appointment of Suzanne Passalacqua to the position of Managing Director and Chief Financial Officer.
  • Currently Senior Vice President & Chief Compliance Officer, Passalacqua will assume the new role on October 31st.
  • During her tenure at Carrick, Suzanne has been responsible for supporting the capital optimization and operational efficiency in portfolio companies and potential investments, and compliance.
  • "I am honored to take on this responsibility and to meet the challenge of this new role," said Suzanne Passalacqua.

Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination

Retrieved on: 
Monday, December 19, 2022
Breast cancer, CDK, Trial of the century, Patient, ESR1, Gastroenterology, SERD, Food, Menarini, Progression-free survival, Fast Track, DOR, Roche, Biology, ORR, ER, FDA, Safety, Inflammation, Clinical trial, Carrick, Research and development, IND, Fulvestrant, Infection, Therapy, PFS, Analgesic, Cell cycle, Research, CDK7, Cardiology, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Development, Prostate cancer, Pharmaceutical industry

DUBLIN and FLORENCE, Italy, Dec. 19, 2022 /PRNewswire/ -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today announced a clinical trial collaboration and supply agreement.

Key Points: 
  • "We are excited to initiate this collaboration with Menarini to explore the potential of samuraciclib in combination with elacestrant for the treatment of advanced breast cancer," said Tim Pearson, Chief Executive Officer of Carrick Therapeutics.
  • "Our pre-clinical work and prior clinical studies have validated the biology for SERD combinations with CDK7, pointing to potential synergies when combining samuraciclib with Menarini's oral SERD, elacestrant.
  • This collaboration represents a shared commitment to maximizing the potential of novel combination therapies to improve outcomes for people living with breast cancer."
  • In addition to samuraciclib, Carrick is also developing a novel CDK12/13 inhibitor / Cyclin-K glue-degrader which has advanced into IND enabling toxicology studies.

Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination

Retrieved on: 
Monday, December 19, 2022
Breast cancer, CDK, Trial of the century, Patient, ESR1, Gastroenterology, SERD, Food, Menarini, Progression-free survival, Fast Track, DOR, Roche, Biology, ORR, ER, FDA, Safety, Inflammation, Clinical trial, Carrick, Research and development, IND, Fulvestrant, Infection, Therapy, PFS, Analgesic, Cell cycle, Research, CDK7, Cardiology, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Development, Prostate cancer, Pharmaceutical industry

DUBLIN and FLORENCE, Italy, Dec. 19, 2022 /PRNewswire/ -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today announced a clinical trial collaboration and supply agreement.

Key Points: 
  • "We are excited to initiate this collaboration with Menarini to explore the potential of samuraciclib in combination with elacestrant for the treatment of advanced breast cancer," said Tim Pearson, Chief Executive Officer of Carrick Therapeutics.
  • "Our pre-clinical work and prior clinical studies have validated the biology for SERD combinations with CDK7, pointing to potential synergies when combining samuraciclib with Menarini's oral SERD, elacestrant.
  • This collaboration represents a shared commitment to maximizing the potential of novel combination therapies to improve outcomes for people living with breast cancer."
  • In addition to samuraciclib, Carrick is also developing a novel CDK12/13 inhibitor / Cyclin-K glue-degrader which has advanced into IND enabling toxicology studies.

Leading EdTech Solutions Company Everspring Names Beth Hollenberg as New Chief Executive Officer

Retrieved on: 
Tuesday, December 13, 2022
Welfare, ABV, Dance or Die (band), Insan, The Washington Post, JD, EVP, Carrick, Approach, SCORE! Educational Centers, SCORE, K-12, Stanford University, Kaplan, Policy, Stanford Law School, Growth, Multimedia, Education, Health, University, Student, Management, Campus, Sociology

CHICAGO, Dec. 13, 2022 /PRNewswire/ -- Everspring, Inc., the leading provider of high-quality online marketing and education solutions for higher education, today announced that Beth Hollenberg has been appointed as its Chief Executive Officer. Hollenberg, who co-founded the company and most recently served as its President, is an accomplished executive who brings a demonstrated record of success building companies in the K-12, higher education, and professional education services sectors.

Key Points: 
  • CHICAGO, Dec. 13, 2022 /PRNewswire/ -- Everspring, Inc., the leading provider of high-quality online marketing and education solutions for higher education, today announced that Beth Hollenberg has been appointed as its Chief Executive Officer.
  • Hollenberg is succeeding Jeff Conlon, the company's co-founder, who is stepping away from his day-to-day role overseeing Everspring.
  • I look forward to working with the Everspring team to take the company and our partners to the next level."
  • Everspring is a leading provider of education technology and service solutions for higher education.

Bishop Fox Secures $75 Million in Growth Funding from Carrick Capital Partners

Retrieved on: 
Thursday, July 14, 2022
Technology, Wenner, NPS, ARR, Area 1 Security, Richard Foxe, Education, Global, Equifax, Cloudflare, Solution, IOT, Advisory Council, Triage, Carrick, Globe Telecom, LinkedIn, ABV, Organization, Sonos, RELX, CEO, Penelope, GLOBE, Government, Chief executive officer, Legislation, Approach, SentinelOne, Mentorship, Automation, Product management, Twitter, Curriculum, Workforce, NowSecure, Google, Industry, Partnership, University, Risk management, Renewable energy, Video game, Stevie Awards, Engineering, Cosmos

PHOENIX, July 14, 2022 (GLOBE NEWSWIRE) -- Bishop Fox , the leading authority in offensive security, today announced $75 million in Series B funding from growth-oriented investment firm, Carrick Capital Partners .

Key Points: 
  • PHOENIX, July 14, 2022 (GLOBE NEWSWIRE) -- Bishop Fox , the leading authority in offensive security, today announced $75 million in Series B funding from growth-oriented investment firm, Carrick Capital Partners .
  • These initiatives place Bishop Fox in a unique position to lead the market in both areas.
  • Additionally, Bishop Foxs comprehensive offensive security solutions and industry-leading attack surface management technology help organizations proactively improve their security posture.
  • This capital will fuel additional innovation in our Cosmos platform, investment in our people, and expansion of Bishop Fox Academy.

CARRICK CAPITAL PARTNERS ANNOUNCES THREE PORTFOLIO COMPANY EXITS

Retrieved on: 
Thursday, December 16, 2021
Chief executive officer, ABV, KKR, McMorris, Sale, SAN, Industry, Carrick, Data management, CEO, McKesson Corporation, Approach, Merck, Investment, Software, Financial services

SAN FRANCISCO and NEWPORT BEACH, Calif., Dec. 16, 2021 /PRNewswire/ -- Carrick Capital Partners, a growth-oriented investment firm focused on software and software-enabled businesses, today announced the completion of three portfolio company sales in the final quarter of 2021.

Key Points: 
  • SAN FRANCISCO and NEWPORT BEACH, Calif., Dec. 16, 2021 /PRNewswire/ -- Carrick Capital Partners, a growth-oriented investment firm focused on software and software-enabled businesses, today announced the completion of three portfolio company sales in the final quarter of 2021.
  • Carrick Capital Partners will have an equity interest in the combined business.
  • Headquartered in San Francisco and Newport Beach, Carrick Capital Partners is a growth-oriented investment firm that utilizes ABV (Approach to Building Value) to operationally scale fast-growing, technology-enabled businesses.
  • The portfolio companies identified and described herein do not represent all of the portfolio companies purchased, sold, or recommended for funds advised by Carrick.

Carrick Capital Partners Promotes Ivan Whittey to Director

Retrieved on: 
Monday, September 27, 2021
ABV, Wharton School of the University of Pennsylvania, Software, Business, University, Dance or Die (band), Marshall School, SAN, Approach, MBA, Chief executive officer, Carrick, Investment, Exigent circumstance, BS, Industry, Bank

SAN FRANCISCO and NEWPORT BEACH, Calif., Sept. 27, 2021 /PRNewswire/ --Carrick Capital Partners, a growth-oriented investment firm focused on software and software-enabled businesses, today announced the promotion of Ivan Whittey to Director.

Key Points: 
  • SAN FRANCISCO and NEWPORT BEACH, Calif., Sept. 27, 2021 /PRNewswire/ --Carrick Capital Partners, a growth-oriented investment firm focused on software and software-enabled businesses, today announced the promotion of Ivan Whittey to Director.
  • Formerly a Vice President at Carrick Capital Partners, Ivan leads the thematic sourcing efforts within education technology and regulatory technology.
  • This well-deserved promotion is a reflection on his outstanding contributions to the firm," explained Carrick Capital Partners Co-CEO Marc McMorris.
  • Prior to joining Carrick, Ivan was on the investing teams of Spire Capital Partners and Lindsay Goldberg.

Kevin Weinstein Joins Renalogic as CEO to Fuel Growth

Retrieved on: 
Tuesday, August 10, 2021
Kidney, Risk management, Industry, CEO, Incidence, Dialysis, Risk, Allscripts, Carrick, Organization, Chief executive officer, ABV, Moody, Evol (Future album), Mark (given name), Approach, Chronic kidney disease, Board, Director, Population, History, Board of directors, CKD, Disease, Growth, Pharmaceutical industry, Health insurance

PHOENIX and CHICAGO, Aug. 10, 2021 /PRNewswire/ -- Renalogic, the industry leader in dialysis risk management and cost containment, announced today the appointment of Kevin Weinstein as Chief Executive Officer.

Key Points: 
  • PHOENIX and CHICAGO, Aug. 10, 2021 /PRNewswire/ -- Renalogic, the industry leader in dialysis risk management and cost containment, announced today the appointment of Kevin Weinstein as Chief Executive Officer.
  • "Kevin's experience launching healthcare solutions that challenge the status quo will set a new pace for our accelerated growth."
  • Immediately prior to joining Renalogic, Weinstein was President of population health technology company Azara Healthcare.
  • As part of its commitment to accelerating growth, Renalogic participated in a growth recapitalization with Carrick Capital Partners, which was announced in March 2021.

Carrick Capital Partners Appoints Chris Wenner Managing Director

Retrieved on: 
Wednesday, January 9, 2019
Software, Carrick, Wenner, Software as a service, Computing

SAN FRANCISCOand NEWPORT BEACH, Calif., Jan. 9, 2019 /PRNewswire/ --Carrick Capital Partners, an investment firm focused on technology-enabled businesses including SaaS, Software, BPO and Transaction Processing, today announced the promotion of Chris Wenner to Managing Director.

Key Points: 
  • SAN FRANCISCOand NEWPORT BEACH, Calif., Jan. 9, 2019 /PRNewswire/ --Carrick Capital Partners, an investment firm focused on technology-enabled businesses including SaaS, Software, BPO and Transaction Processing, today announced the promotion of Chris Wenner to Managing Director.
  • He started as an associate and has earned frequent promotions for exceptional performance and the value he brings to our portfolio companies," explained Carrick Capital Partners Co-Founder and Managing Director Jim Madden.
  • Chris Wenner originally joined Carrick Capital Partners in 2012.
  • We couldn't be happier to welcome him as a partner today," added Carrick Capital Partners Co-Founder and Managing Director Marc McMorris.